Colorectal Cancer Diagnosis and Therapeutics Market
Colorectal Cancer Diagnosis and Therapeutics Market Size, Share & Trends Analysis by Type (Adenocarcinomas, Carcinoid Tumors, Lymphomas, Sarcomas, and Gastrointestinal Stromal Tumors (GISTS)), by Diagnosis (Digital Rectal Examination, Fecal Occult Blood Test, Flexible Sigmoidoscopy, Colonoscopy, and Others (Biopsy)), By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), By End-User (Multispecialty Hospitals, and Cancer Research Centers), Forecast Period (2026-2035)
Industry Overview
Colorectal cancer diagnosis and therapeutics market was valued at $13.6 billion in 2025 and is projected to reach $20.9 billion by 2035, growing at a CAGR of 4.5% during the forecast period (2026-2035). The global market is driven by the increasing incidence of the disease, fueled by lifestyle factors and an aging population. Key factors include advancements in diagnostic technologies, rising healthcare spending, growing government initiatives, and the development of targeted and personalized therapies. Regulatory approvals for new treatments and a greater focus on early detection through non-invasive screenings are also significant market drivers.
Market Dynamics
Rising Global Disease Burden & Demographic Risk Factors
One of the most fundamental drivers for the colorectal cancer (CRC) diagnostics and therapeutics market is the increasing prevalence and incidence of CRC worldwide. Aging populations—particularly in developed markets are at elevated risk, and as more people live into older age, the number of CRC cases naturally increases. Additionally, lifestyle factors such as poor diet, physical inactivity, obesity, and smoking are contributing to the rising incidence, particularly in regions undergoing rapid economic change. This growing disease burden drives demand both for screening/diagnostic tools (to catch cancer early) and for therapeutic interventions (since more patients will require treatment).
Technological Innovation & Advanced Diagnostics
Technological progress in diagnostics is a major engine propelling this market. The development of non-invasive, highly sensitive screening tests such as liquid biopsies (circulating tumor DNA), stool DNA assays, and next-generation sequencing (NGS) for molecular profiling is enabling earlier and more accurate detection of CRC. These advanced diagnostics improve risk stratification, guide personalized treatment (via companion diagnostics), and support monitoring for recurrence. Moreover, innovations like AI-powered imaging and decision-support systems (especially integrating patient metadata) are enhancing diagnostic precision and helping clinicians make more informed decisions. The adoption of such technologies is fueling growth in both diagnostic and therapeutic segments.
Personalized Therapies, Immunotherapy & Strategic Investment
Therapeutic innovation is another critical growth driver. There is a strong shift toward personalized medicine, where therapies are tailored to a patient’s genetic and molecular tumor profile. Targeted therapies (e.g., EGFR inhibitors) and immunotherapies (like immune checkpoint inhibitors) are increasingly used in CRC, especially for specific subtypes (e.g., MSI-high). Meanwhile, significant R&D investments, strategic M&A, and partnerships between diagnostic companies and pharmaceutical firms are accelerating the development of integrated solutions diagnostics that link directly to therapies. These dynamics not only improve patient outcomes but also strengthen the commercial case for more advanced diagnostics and next-generation therapies.
Market Segmentation
- Based on the types, the market is segmented into adenocarcinomas, carcinoid tumors, lymphomas, sarcomas, and gastrointestinal stromal tumors (GISTS).
- Based on the diagnosis, the market is segmented into digital rectal examination, fecal occult blood test, flexible sigmoidoscopy, colonoscopy, and others (Biopsy).
- Based on the treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.
- Based on the end user, the market is segmented into multispecialty hospitals and cancer research centers.
Adenocarcinomas Segment to Grow at a Considerable Market Share
Among all the listed segmentation categories, Adenocarcinomas by cancer type represent the largest and most dominant segment in the global colorectal cancer diagnosis and therapeutics market. This is primarily because more than 90% of colorectal cancer cases diagnosed worldwide are adenocarcinomas, making it the primary form of CRC addressed through screening programs, clinical guidelines, and treatment protocols. The significant burden of adenocarcinoma drives high utilization of advanced diagnostic methods such as colonoscopy, biopsy, stool DNA tests, and molecular biomarker profiling. Correspondingly, the treatment landscape, including surgery as the first-line curative option, followed by chemotherapy regimens like FOLFOX/FOLFIRI, and increasingly targeted therapies such as VEGF and EGFR inhibitors (e.g., bevacizumab, cetuximab), as well as checkpoint immunotherapies, is largely developed around this subtype. Ongoing R&D pipelines, clinical trials, and regulatory approvals are predominantly focused on adenocarcinoma, further reinforcing its commercial and clinical dominance.
Additionally, its high prevalence among the aging population and growing incidence in younger adults worldwide are creating sustained market expansion opportunities for both diagnostics and therapeutics. The high healthcare spending allocated to managing adenocarcinoma from early detection to advanced-stage treatment supports larger revenue generation compared to rare CRC types like GISTs, carcinoid tumors, lymphomas, and sarcomas. Therefore, the adenocarcinoma segment will continue to lead global market growth throughout the forecast period due to its overwhelming share of CRC cases, broad treatment availability, and continual innovation pipeline.
Colonoscopy: A Key Segment in Market Growth
Among all the segments in the colorectal cancer market across diagnosis, treatment, and end-user categories, colonoscopy stands out as the key segment driving market growth. Colonoscopy remains the gold-standard diagnostic method due to its high accuracy, ability to detect early-stage malignancies, and its unique advantage of enabling simultaneous polyp removal during screening. The rising global incidence of colorectal cancer, driven by aging populations, sedentary lifestyles, obesity, and dietary risks, has significantly increased the demand for colonoscopic screening.
Many countries have strengthened national screening programs, which mandate regular colonoscopy for individuals above 50 years or those at high risk, thereby expanding procedural volumes worldwide. Technological advancements, such as high-definition imaging, AI-driven polyp detection, and minimally invasive endoscopic tools, have further enhanced diagnostic precision and patient outcomes.
Additionally, growing awareness of preventive healthcare and early cancer detection is encouraging more individuals to opt for colonoscopy over other diagnostic methods like fecal tests or sigmoidoscopy. Healthcare providers and governments are also increasing investments in endoscopic infrastructure and skilled professionals to improve accessibility. With its superior diagnostic capability, therapeutic potential during screening, and expanding global adoption, colonoscopy remains the most influential segment, contributing significantly to market expansion.
Regional Outlook
The global colorectal cancer diagnosis and therapeutics market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US is the dominant single-country contributor to the global colorectal cancer (CRC) diagnosis and therapeutics market. North America represents the largest regional market share, around 40–45% of the global CRC diagnostics and treatment market. North America, the US’s stronghold, is driven by its advanced healthcare infrastructure, extensive public and private CRC screening programs, high levels of awareness, and the rapid adoption of innovative diagnostic technologies (such as stool-DNA tests and circulating tumor DNA assays).
Additionally, the US leads in therapeutic innovation: it is home to many of the top pharmaceutical and biotech companies developing targeted therapies, immunotherapies, and precision medicine regimens for CRC, coupled with substantial clinical trial activity. Growth Market Reports+1 Furthermore, favorable reimbursement policies and strong payer support for biomarker-driven treatment facilitate swift uptake of new therapies. In diagnostics, the U.S. has widespread colonoscopy programs, as well as growing adoption of non-invasive at-home screening tests, supported by payer systems and public health initiatives.
Market Players Outlook
The major companies operating in the global colorectal cancer diagnosis and therapeutics market include Amgen Inc., Bristol Myers Squibb (BMS), Eli Lilly and Co., F. Hoffmann-La Roche AG, Merck & Co., Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
- In October 2025, a Combination of immunotherapy and targeted therapy enhances survival for advanced colorectal cancer patients, marking a significant milestone. A study from UCLA reveals that the combination of zanzalintinib (a targeted therapy) and atezolizumab (an immune checkpoint inhibitor) offers better longevity and disease control compared to regorafenib, the standard drug. This is the first trial showing survival improvement in 95% of metastatic colorectal cancer patients—those who usually do not respond to existing immunotherapies. The research underscores the urgent need for effective treatments, as currently only about 15% of such patients survive for five years.
- In January 2025, Guardant Health's liquid biopsy test, Shield, received FDA approval as a less-invasive alternative to colonoscopies for cancer detection. Although experts view this approval as a promising development, they note that the test is less accurate in identifying precancerous or early-stage cancers compared to traditional colonoscopy methods.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global colorectal cancer diagnosis and therapeutics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Colorectal Cancer Diagnosis and Therapeutics Market Sales Analysis – Diagnosis | Diagnosis | Treatment ($ Million)
- Colorectal Cancer Diagnosis and Therapeutics Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Colorectal Cancer Diagnosis and Therapeutics Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Colorectal Cancer Diagnosis and Therapeutics Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Colorectal Cancer Diagnosis and Therapeutics Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Colorectal Cancer Diagnosis and Therapeutics Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Colorectal Cancer Diagnosis and Therapeutics Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Colorectal Cancer Diagnosis and Therapeutics Market Revenue and Share by Manufacturers
- Colorectal Cancer Diagnosis and Therapeutics Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Amgen Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Bristol Myers Squibb (BMS)
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Eli Lilly and Co.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Hoffmann-La Roche AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co., Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Amgen Inc.
- Key Company Analysis
- Global Colorectal Cancer Diagnosis and Therapeutics Market Sales Analysis by Diagnosis ($ Million)
- Adenocarcinomas
- Carcinoid Tumors
- Lymphomas
- Sarcomas
- Gastrointestinal Stromal Tumors (GISTS)
- Global Colorectal Cancer Diagnosis and Therapeutics Market Sales Analysis by Diagnosis ($ Million)
- Digital Rectal Examination
- Fecal Occult Blood Test
- Flexible Sigmoidoscopy
- Colonoscopy
- Others (Biopsy)
- Global Colorectal Cancer Diagnosis and Therapeutics Market Sales Analysis by Treatment ($ Million)
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Global Colorectal Cancer Diagnosis and Therapeutics Market Sales Analysis by End-User ($ Million)
- Multispecialty Hospitals
- Cancer Research Centers
- Regional Analysis
- North American Colorectal Cancer Diagnosis and Therapeutics Market Sales Analysis – Diagnosis | Diagnosis | Treatment | End-User | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Colorectal Cancer Diagnosis and Therapeutics Market Sales Analysis – Diagnosis | Diagnosis | Treatment | End-User | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Colorectal Cancer Diagnosis and Therapeutics Market Sales Analysis – Diagnosis | Diagnosis | Treatment | End-User | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Colorectal Cancer Diagnosis and Therapeutics Market Sales Analysis – Diagnosis | Diagnosis | Treatment | End-User | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Agilent Technologies
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol-Myers Squibb
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Danaher Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Exact Sciences
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche / Genentech
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fujifilm Holdings Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Guardant Health
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Illumina, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson (Janssen)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Olympus Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Thermo Fisher Scientific
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
2. Global Adenocarcinomas Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Carcinoid Tumors Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Lymphomas Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Sarcomas Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Gastrointestinal Stromal Tumors (GISTS) Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
8. Global Digital Rectal Examination Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Fecal Occult Blood Test Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Flexible Sigmoidoscopy Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Colonoscopy Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Other Diagnosis Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
14. Global Surgery For Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Radiation Therapy For Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Chemotherapy For Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Targeted Therapy For Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
18. Global Immunotherapy For Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
19. Global Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by End-Users, 2025–2035 ($ Million)
20. Global Colorectal Cancer Diagnosis and Therapeutics For Multispecialty Hospitals Market Research and Analysis by Region, 2025–2035 ($ Million)
21. Global Colorectal Cancer Diagnosis and Therapeutics For Cancer Research Centers Market Research and Analysis by Region, 2025–2035 ($ Million)
22. Global Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
23. North American Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Country, 2025–2035 ($ Million)
24. North American Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Type, 2025–2035 ($ Million)
25. North American Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
26. North American Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
27. North American Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by End-Users, 2025–2035 ($ Million)
28. European Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Country, 2025–2035 ($ Million)
29. European Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Type, 2025–2035 ($ Million)
30. European Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
31. European Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
32. European Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by End-Users, 2025–2035 ($ Million)
33. Asia-Pacific Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Country, 2025–2035 ($ Million)
34. Asia-Pacific Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Type, 2025–2035 ($ Million)
35. Asia-Pacific Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
36. Asia-Pacific Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
37. Asia-Pacific Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by End User, 2025–2035 ($ Million)
38. Rest of the World Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
39. Rest of the World Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Type, 2025–2035 ($ Million)
40. Rest of the World Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Diagnosis, 2025–2035 ($ Million)
41. Rest of the World Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by Treatment, 2025–2035 ($ Million)
42. Rest of the World Colorectal Cancer Diagnosis and Therapeutics Market Research and Analysis by End User, 2025–2035 ($ Million)
1. Global Colorectal Cancer Diagnosis and Therapeutics Market Share by Cancer Type, 2025 vs 2035 (%)
2. Global Adenocarcinomas Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
3. Global Carcinoid Tumors Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
4. Global Lymphomas Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
5. Global Sarcomas Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
6. Global Gastrointestinal Stromal Tumors (GISTs) Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
7. Global Colorectal Cancer Diagnosis and Therapeutics Market Share by Diagnosis Type, 2025 vs 2035 (%)
8. Global Digital Rectal Examination Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
9. Global Fecal Occult Blood Test Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
10. Global Flexible Sigmoidoscopy Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
11. Global Colonoscopy Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
12. Global Other Diagnosis Methods Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
13. Global Colorectal Cancer Diagnosis and Therapeutics Market Share by Treatment Type, 2025 vs 2035 (%)
14. Global Surgery for Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
15. Global Radiation Therapy for Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
16. Global Chemotherapy for Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
17. Global Targeted Therapy for Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
18. Global Immunotherapy for Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
19. Global Colorectal Cancer Diagnosis and Therapeutics Market Share by End-Users, 2025 vs 2035 (%)
20. Global Multispecialty Hospitals Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
21. Global Cancer Research Centers Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 vs 2035 (%)
22. Global Colorectal Cancer Diagnosis and Therapeutics Market Share by Region, 2025 Vs 2035 (%)
23. US Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
24. Canada Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
25. UK Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
26. France Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
27. Germany Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
28. Italy Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
29. Spain Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
30. Russia Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
31. Rest of Europe Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
32. India Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
33. China Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
34. Japan Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
35. South Korea Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
36. Australia and New Zealand Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
37. ASEAN Economies Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
38. Rest of Asia-Pacific Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
39. Latin America Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
40. Middle East and Africa Colorectal Cancer Diagnosis and Therapeutics Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Colorectal Cancer Diagnosis and Therapeutics Market in 2025 is estimated to be around $13.6 billion.
North America holds the largest share in the Colorectal Cancer Diagnosis and Therapeutics Market.
Leading players in the Colorectal Cancer Diagnosis and Therapeutics Market include Amgen Inc., Bristol Myers Squibb (BMS), Eli Lilly and Co., F. Hoffmann-La Roche AG, Merck & Co., Inc., among others.
Colorectal Cancer Diagnosis and Therapeutics Market is expected to grow at a CAGR of 4.5% from 2026 to 2035.
Rising colorectal cancer prevalence, advancements in early detection technologies, and increasing adoption of targeted therapies are driving the Colorectal Cancer Diagnosis and Therapeutics Market growth.
